Literature DB >> 12811514

The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.

Leo J Ostruszka1, Donna S Shewach.   

Abstract

PURPOSE: Cytotoxicity from the anticancer drug 2',2'-difluoro-2'-deoxycytidine (dFdCyd) has been correlated with its incorporation into DNA. However, cytotoxicity may also result from inhibition of DNA synthesis, due to either (1) dFdCyd diphosphate-mediated inhibition of ribonucleotide reductase, or (2) direct inhibition of DNA polymerases by the 5'-triphosphate of dFdCyd (dFdCTP). To elucidate the role of DNA synthesis inhibition in the cytotoxicity of dFdCyd, we compared dFdCyd to hydroxyurea (HU), a ribonucleotide reductase inhibitor, and aphidicolin, an inhibitor of DNA polymerases, in the U251 and D54 human glioblastoma cell lines.
METHODS: Sensitivity to dFdCyd, HU, and aphidicolin were determined using a colony formation assay. The effects of these drugs on DNA synthesis were measured by dual parameter flow cytometry, while the effects on nucleotide pool levels were analyzed by high-performance liquid chromatography.
RESULTS: HU and aphidicolin elicited substantially less cytotoxicity than the multi-log killing with dFdCyd. When used at equitoxic concentrations (24-h IC50 values), dFdCyd and HU decreased purine dNTP pools primarily, but dFdCyd was less effective than HU. dFdCyd had decreased dATP by about 80% after 4-12 h, and required 8-24 h to decrease DNA synthesis by 50%. In contrast, HU rapidly depleted dATP by >98% within 2 h, which resulted in >90% inhibition of DNA synthesis. Aphidicolin at a concentration similar to its Ki values for DNA polymerases (1 microM) decreased DNA synthesis by >70% within 2 h. However, this decreased cell survival by only 10% (U251 cells) and 40% (D54 cells).
CONCLUSIONS: These results demonstrate that HU and aphidicolin produced a more rapid and profound inhibition of DNA synthesis than dFdCyd, but resulted in significantly less cytotoxicity. This suggests that inhibition of DNA synthesis accounted for less than one log of the multi-log cytotoxicity observed with dFdCyd, whereas incorporation of dFdCTP into DNA is a more lethal event.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811514     DOI: 10.1007/s00280-003-0661-5

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches.

Authors:  Sheryl A Flanagan; Christina M Krokosky; Sudha Mannava; Mikhail A Nikiforov; Donna S Shewach
Journal:  Mol Pharmacol       Date:  2008-06-05       Impact factor: 4.436

2.  Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor.

Authors:  Jason Boyang Wu; Changhong Shi; Gina Chia-Yi Chu; Qijin Xu; Yi Zhang; Qinlong Li; John S Yu; Haiyen E Zhau; Leland W K Chung
Journal:  Biomaterials       Date:  2015-07-16       Impact factor: 12.479

3.  Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation.

Authors:  Albert J van Hell; Adriana Haimovitz-Friedman; Zvi Fuks; William D Tap; Richard Kolesnick
Journal:  Cell Signal       Date:  2017-02-24       Impact factor: 4.315

4.  Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.

Authors:  Jessica J O'Konek; Brendon Ladd; Sheryl A Flanagan; Mike M Im; Paul D Boucher; Tico S Thepsourinthone; John A Secrist; Donna S Shewach
Journal:  Mutat Res       Date:  2010-01-08       Impact factor: 2.433

Review 5.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

6.  Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer model.

Authors:  Meredith Morgan; Mohamed A El Shaikh; Eyad Abu-Isa; Mary A Davis; Theodore S Lawrence
Journal:  Transl Oncol       Date:  2008-03       Impact factor: 4.243

Review 7.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

8.  Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication.

Authors:  L Boeckemeier; R Kraehenbuehl; A Keszthelyi; M U Gasasira; E G Vernon; R Beardmore; C B Vågbø; D Chaplin; S Gollins; H E Krokan; S A E Lambert; B Paizs; E Hartsuiker
Journal:  Sci Adv       Date:  2020-05-29       Impact factor: 14.136

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.